<DOC>
	<DOCNO>NCT01575925</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( PK ) safety combination pomalidomide ( POM ) + low-dose dexamethasone ( LD-DEX ) subject relapse refractory Multiple Myeloma ( RRMM ) impair renal function .</brief_summary>
	<brief_title>Study Pomalidomide Evaluate Pharmacokinetics Safety Patients With Multiple Myeloma Impaired Renal Function ( POM Renal )</brief_title>
	<detailed_description>The primary objective study determine PK safety combination POM + ( LD-DEX ) subject RRMM impair renal function . The secondary objective study evaluate efficacy POM + ( LD_DEX ) subject RRMM impair renal function . This 3+3 dose escalation design , one cohort patient severely impaired renal function patient ( CrCl &lt; 30 mL/min ) require require dialysis respectively . There also one control cohort normal renal function , patient receive 4 mg POM . Dosing 21 day 28 day cycle .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Must ≥ 18 year time signing informed consent form 2 . Must understand voluntarily sign informed consent document prior studyrelated assessments/procedures 3 . Must able adhere study visit schedule protocol requirement 4 . Must document diagnosis relapse refractory multiple myeloma measurable disease ( serum Mprotein ≥ 0.5 g/dL urine Mprotein ≥ 200 mg/24 hour ) 5 . Must least 1 prior antimyeloma regimen 6 . Must document progression per International Myeloma Working Group uniform response criterion ( Durie , 2006 ) last antimyeloma regimen 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 8 . Females childbearing potential ( FCBP ) must agree utilize two reliable form contraception simultaneously practice complete abstinence heterosexual contact least 28 day start study drug , participate study ( include dose interruption ) , least 28 day study treatment discontinuation , must agree regular pregnancy test timeframe 9 . Females must agree abstain breastfeed study participation 28 follow discontinuation study treatment 10 . Males must agree use latex condom sexual contact FCBP participate study 28 day follow discontinuation study treatment , even undergone successful vasectomy 11 . Males must also agree refrain donate semen sperm pomalidomide 28 day discontinuation study treatment 12 . All subject must agree refrain donate blood study drug 28 day discontinuation study treatment 13 . All subject must agree share medication The presence follow exclude subject enrollment : 1 . Peripheral neuropathy ≥ Grade 2 2 . Nonsecretory multiple myeloma 3 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL Platelet count &lt; 75,000/µL Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior RBC transfusion recombinant human erythropoietin use permit ) Serum glutamic oxaloacetic transaminase/aspartate aminotransferase ( SGOT/AST ) serum glutamic pyruvic transaminase/alanine aminotransferase ( SGPT/ALT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL 4 . Prior history malignancy , disease study , unless subject free malignancy ≥ 5 year initiate study treatment , follow exception : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( T1a T1b use TNM [ tumor , node , metastasis ] clinical staging system ) . 5 . Previous therapy Pomalidomide 6 . Hypersensitivity thalidomide , lenalidomide , dexamethasone 7 . Rash ≥ Grade 3 prior thalidomide lenalidomide therapy 8 . Incidence gastrointestinal disease may significantly alter absorption pomalidomide 9 . Subjects one following : Congestive heart failure ( New York Heart Association Class III IV ) Myocardial infarction within 12 month prior start study treatment Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris 10 . Subjects receive follow within last 14 day initiation study treatment : Plasmapheresis Major surgery ( kyphoplasty consider major surgery ) Radiation therapy ( exception radiation therapy pathological fracture site enhance bone heal treat postfracture pain refractory narcotic analgesic ) Any antimyeloma drug therapy 11 . Use investigational agent within 28 day 5 halflives ( whichever longer ) initiate study treatment 12 . Subjects condition require chronic steroid immunosuppressive treatment , rheumatoid arthritis , multiple sclerosis , lupus , likely need additional steroid immunosuppressive treatment addition study treatment . Includes subject receive corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 3 week prior initiate study treatment 13 . Subjects unable unwilling undergo antithrombotic prophylactic treatment eligible participate study 14 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study 15 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign informed consent form 16 . Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pomalidomide multiple myeloma</keyword>
	<keyword>renal impairment</keyword>
	<keyword>multiple myeloma patient renal impairment</keyword>
	<keyword>Pomalidomide patient renal impairment due multiple myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>RRMM</keyword>
	<keyword>impaired renal function multiple myeloma</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>dialysis</keyword>
	<keyword>POM</keyword>
	<keyword>Pomalyst</keyword>
	<keyword>MM</keyword>
	<keyword>severe renal impairment</keyword>
	<keyword>CrCl ≤ 30 mL/min</keyword>
	<keyword>Creatinine le 30</keyword>
	<keyword>clinical trial subject multiple myeloma renal impairement</keyword>
</DOC>